Summary
5.27 -0.09(-1.68%)11/04/2024
Aldeyra Therapeutics Inc (ALDX)
Aldeyra Therapeutics Inc (ALDX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.68 | 0.66 | 1.42 | 43.57 | 27.50 | 110.83 | -8.77 | -25.63 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.27 | |
| Open | 5.34 | |
| High | 5.39 | |
| Low | 5.09 | |
| Volume | 156,498 | |
| Change | -0.09 | |
| Change % | -1.68 | |
| Avg Volume (20 Days) | 324,049 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 1.97 - 6.55 | |
| Price vs 52 Week High | -19.54% | |
| Price vs 52 Week Low | 167.51% | |
| Range | 1.23 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 319 | |
| EBIDTA | -35,128,232 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 9.25 | |
| Book Value | 1.9090 | |
| Earnings Per Share | -0.5100 | |
| EPS Estimate Current Quarter | -0.1100 | |
| EPS Estimate Next Quarter | -0.1300 | |
| EPS Estimate Current Year | -0.3200 | |
| EPS Estimate Next Year | -0.5700 | |
| Diluted EPS (TTM) | -0.5100 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1429 | |
| Return on equity (TTM) | -0.2394 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.0895 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | -3.4975 | |
| Shares | ||
| Shares Outstanding | 59,414,500 | |
| Shares Float | 43,160,467 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 2.49 | |
| Institutions (%) | 60.88 | |
10/31 07:00 EST - businesswire.com
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. Dr. Stryjew.
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. Dr. Stryjew.
10/03 07:00 EST - businesswire.com
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes pr.
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes pr.
06/20 07:00 EST - businesswire.com
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today. Pipeline Updates Following positive biomarker results in adults, including near-normalization o.
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today. Pipeline Updates Following positive biomarker results in adults, including near-normalization o.
06/13 07:00 EST - businesswire.com
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease. The trial is designed to enable potential resubmission of a dry eye dise.
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease. The trial is designed to enable potential resubmission of a dry eye dise.
06/12 07:00 EST - businesswire.com
Aldeyra Therapeutics to Host Investor Roundtable Q&A
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET. The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session.
Aldeyra Therapeutics to Host Investor Roundtable Q&A
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET. The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session.
06/10 13:25 EST - seekingalpha.com
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.
05/29 07:00 EST - businesswire.com
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jeff.
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jeff.
05/14 10:46 EST - zacks.com
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
05/08 07:00 EST - businesswire.com
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye.
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye.
05/03 08:52 EST - investorplace.com
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
Aldeyra Therapeutics (NASDAQ: ALDX ) just reported results for the first quarter of 2024. Aldeyra Therapeutics reported earnings per share of -14 cents.
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
Aldeyra Therapeutics (NASDAQ: ALDX ) just reported results for the first quarter of 2024. Aldeyra Therapeutics reported earnings per share of -14 cents.
04/25 07:00 EST - businesswire.com
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa. Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic h.
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa. Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic h.
04/22 10:46 EST - zacks.com
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
04/21 08:45 EST - 247wallst.com
Buffett Grabs More of This Stock, Plus Other Notable Insider Buying
At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.
Buffett Grabs More of This Stock, Plus Other Notable Insider Buying
At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.
04/18 07:00 EST - businesswire.com
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City. Aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the Aldey.
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City. Aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the Aldey.
04/07 08:55 EST - 247wallst.com
Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter
Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter
Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
04/06 07:41 EST - zacks.com
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
03/28 07:00 EST - businesswire.com
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Foll.
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Foll.
03/24 00:46 EST - seekingalpha.com
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.